Evidence map›Paper›PMID 42026067›Full record

ArticleNature communications2026

Type I interferon drives T cell responses to amyloid beta in the central nervous system.

Julius J Michel, Khwab Sanghvi, Jakob Rosenbauer, Lea Humbs, Clara Tejido Dierssen, Saskia Grudzenski-Theis, Viktoria Sachs, Kristine Jähne, Karoline Degenhardt, Lutz Frölich and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julius J Michel *Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Khwab Sanghvi *Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-0958-1433
Jakob RosenbauerClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lea HumbsClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Clara Tejido DierssenClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Saskia Grudzenski-TheisDepartment of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Viktoria SachsClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kristine JähneClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Karoline DegenhardtDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-1382-5912
Lutz FrölichDivision of Geriatric Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.ORCID 0000-0003-1494-0813
Jochen HermsCenter for Neuropathology and Prion Research, Ludwig-Maximilians University Munich, Munich, Germany.ORCID 0000-0002-6201-1042
Marc FatarDepartment of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Michael PlattenClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4746-887X
Lukas BunseClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. l.bunse@dkfz-heidelberg.de.ORCID 0000-0002-4490-7574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid beta (Aβ) plaque deposition in the central nervous system (CNS) is a hallmark of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), triggering robust innate immune responses. However, the role of the adaptive immune system remains less well understood. Here we show the immune microenvironment dynamics in APP23 transgenic (APP23-tg) mice modelling CNS amyloid pathology, using single-cell transcriptomics. We observed a marked increase in T-cell populations during late disease stages, particularly CD8⁺ T-cells that clustered around Aβ plaques, suggesting a targeted immune response. Among these, we identified an Aβ plaque-associated subset of CD8⁺ T cells expressing interferon-stimulated genes (ISGs), which promoted Type-I interferon signaling. This subset also produced CXCL10, facilitating the recruitment of non-ISG T cells through the CXCL10-CXCR3 axis. Importantly, similar Type-I interferon responses were detected near plaques in human CNS amyloid pathology. Together, these findings highlight a shift from microglia-driven to T-cell-mediated neuroinflammation as amyloid pathology progresses, with implications for time-resolved therapy development.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCD8-Positive T-LymphocytesCentral Nervous SystemInterferon Type IAmyloid beta-Protein PrecursorAnimalsBrainChemokine CXCL10Disease Models, AnimalFemaleHumansMiceMice, Inbred C57BLMice, TransgenicMicrogliaAmyloid beta-PeptidesAmyloid beta-Protein PrecursorChemokine CXCL10Cxcl10 protein, mouseCxcr3 protein, mouseInterferon Type IReceptors, CXCR3

Identifiers

PMID42026067
PMCPMC13106858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.